loading
전일 마감가:
$3.14
열려 있는:
$3.07
하루 거래량:
56,444
Relative Volume:
1.33
시가총액:
$10.24M
수익:
순이익/손실:
$-7.77M
주가수익비율:
-0.3524
EPS:
-9.9046
순현금흐름:
$-6.52M
1주 성능:
-10.51%
1개월 성능:
-33.40%
6개월 성능:
+115.43%
1년 성능:
-62.51%
1일 변동 폭
Value
$3.07
$3.66
1주일 범위
Value
$3.00
$4.04
52주 변동 폭
Value
$1.31
$9.90

Adial Pharmaceuticals Inc Stock (ADIL) Company Profile

Name
명칭
Adial Pharmaceuticals Inc
Name
전화
434-422-9800
Name
주소
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Name
직원
6
Name
트위터
@AdialPharma
Name
다음 수익 날짜
2026-11-12
Name
최신 SEC 제출 서류
Name
ADIL's Discussions on Twitter

Compare ADIL vs VRTX, MRNA, REGN, ARGX, ONC

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
ADIL icon
ADIL
Adial Pharmaceuticals Inc
3.49 10.24M 0 -7.77M -6.52M -9.9046
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
499.74 126.66B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
218.01 87.04B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
790.74 81.41B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
819.14 51.51B 4.16B 1.29B 734.26M 19.58
ONC icon
ONC
Beone Medicines Ltd Adr
369.06 41.75B 5.76B 514.49M 1.10B 4.4813

Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2026-08-03 개시 Alliance Global Partners Buy
2024-11-14 개시 Rodman & Renshaw Buy
2018-10-30 개시 Maxim Group Buy
2018-10-11 개시 Dawson James Buy

Adial Pharmaceuticals Inc 주식(ADIL)의 최신 뉴스

pulisher
Oct 16, 2026

Adial Pharmaceuticals appoints David Rubenstein as chief scientist By Investing.com - Investing.com South Africa

Oct 16, 2026
pulisher
Oct 16, 2026

Adial Pharmaceuticals Appoints David Rubenstein as Chief Scientist - citybiz

Oct 16, 2026
pulisher
Oct 16, 2026

Adial Pharmaceuticals appoints David Rubenstein as chief scientist By Investing.com - Investing.com India

Oct 16, 2026
pulisher
Oct 16, 2026

Adial Pharmaceuticals names former Dermavant CSO as chief scientist - StreetInsider

Oct 16, 2026
pulisher
Oct 16, 2026

Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis - Yahoo! Finance Canada

Oct 16, 2026
pulisher
Oct 16, 2026

The scientist who led development of an FDA-approved skin treatment will guide Adial's ulcerative colitis drug. - Stock Titan

Oct 16, 2026
pulisher
Oct 03, 2026

Adial Pharmaceuticals Adjourns Meeting Pending Nasdaq Listing Decision - The Globe and Mail

Oct 03, 2026
pulisher
Oct 02, 2026

Adial Pharmaceuticals adjourns votes pending Nasdaq listing approval, reconvenes Oct 15 - TradingView

Oct 02, 2026
pulisher
Sep 30, 2026

Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView

Sep 30, 2026
pulisher
Sep 30, 2026

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Sep 30, 2026
pulisher
Sep 30, 2026

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.

Sep 30, 2026
pulisher
Sep 30, 2026

A new hire's right to buy 155,446 Adial shares vests over four years. - Stock Titan

Sep 30, 2026
pulisher
Sep 21, 2026

Director at Adial Pharma (NASDAQ: ADIL) gets 25,666 stock options - Stock Titan

Sep 21, 2026
pulisher
Sep 16, 2026

Adial Pharmaceuticals Removes Penalty Provisions in PIPE and Note Exchange to Restore Nasdaq Compliance - TradingView

Sep 16, 2026
pulisher
Sep 14, 2026

Why Did Adial Pharmaceuticals (ADIL) Stand Out? - Kalkine Media

Sep 14, 2026
pulisher
Sep 12, 2026

Why Did Adial Pharmaceuticals (ADIL) Stand Out? - kalkinemedia.com

Sep 12, 2026
pulisher
Sep 04, 2026

Adial Pharmaceuticals Inc Warrant (ADILW) Key Financial Ratios – Valuation, Profitability & More - Value Research

Sep 04, 2026
pulisher
Aug 29, 2026

Adial Pharmaceuticals to replace CEO and CFO after 2026 annual meeting - scanx.trade

Aug 29, 2026
pulisher
Aug 28, 2026

Adial PharmaceuticalsProposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling StockholdersSEC Filing - TradingView

Aug 28, 2026
pulisher
Aug 28, 2026

Adial Pharmaceuticals files prospectus for resale of 25.1 million shares - scanx.trade

Aug 28, 2026
pulisher
Aug 25, 2026

Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView

Aug 25, 2026
pulisher
Aug 25, 2026

Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Moomoo

Aug 25, 2026
pulisher
Aug 25, 2026

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Aug 25, 2026
pulisher
Aug 25, 2026

A new Adial employee gets a 307,814-share option at $5.76 - Stock Titan

Aug 25, 2026
pulisher
Aug 24, 2026

Adial (ADIL) Financial Update: Profit Per Share Surpasses Its Benchmark in the Latest Reading; Session Move - vinanet.vn

Aug 24, 2026
pulisher
Aug 21, 2026

Adial Pharmaceuticals Faces Nasdaq Listing Compliance Challenge - TipRanks

Aug 21, 2026
pulisher
Aug 21, 2026

Adial Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Aug 21, 2026
pulisher
Aug 21, 2026

Adial (ADIL) Watch: Ends Up by 5.42% at $6.22 in the Latest Reading; Price Context: $5.91 and $6.53 Define the Nearby Reference Levels in the Latest SessionSkew Index - vinanet.vn

Aug 21, 2026
pulisher
Aug 18, 2026

Adial (ADIL) Financial Update: EPS Exceeds Its Estimate on the Day; Post-Report Move: Shares Move 9.22% Up at the CloseRevenue Breakdown Analysis - vinanet.vn

Aug 18, 2026
pulisher
Aug 17, 2026

Adial Pharmaceuticals (ADIL) Jumps 15% as Trading Volume AcceleratesFade Trade - vinanet.vn

Aug 17, 2026
pulisher
Aug 17, 2026

Adial Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet

Aug 17, 2026
pulisher
Aug 17, 2026

Adial Closes $32M Tranche of $64M Financing for Ulcerative Colitis Drug Development - Minichart

Aug 17, 2026
pulisher
Aug 17, 2026

Form 8K Adial Pharmaceuticals Inc For: 17 August By Investing.com - Investing.com Nigeria

Aug 17, 2026
pulisher
Aug 17, 2026

Adial Pharmaceuticals Releases Q2 2026 Financial Results - news.alphastreet.com

Aug 17, 2026
pulisher
Aug 17, 2026

Form 8K Adial Pharmaceuticals Inc For: 17 August By Investing.com - Investing.com Canada

Aug 17, 2026
pulisher
Aug 17, 2026

Form 8K Adial Pharmaceuticals Inc For: 17 August By Investing.com - Investing.com UK

Aug 17, 2026
pulisher
Aug 17, 2026

Weekly Recap: Cash shortfall, warrant reliance and CEO succession, CFO exit - TradingView

Aug 17, 2026
pulisher
Aug 17, 2026

Adial Reports $52 Million Second-Quarter Net Loss After Azora Acquisition - Quiver Quantitative

Aug 17, 2026
pulisher
Aug 17, 2026

Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update - The Manila Times

Aug 17, 2026
pulisher
Aug 17, 2026

Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update - GlobeNewswire

Aug 17, 2026
pulisher
Aug 15, 2026

ADIL Q1 2026 Earnings: EPS Surprise Amid Revenue AbsenceDividend Growth Analysis - vinanet.vn

Aug 15, 2026
pulisher
Aug 15, 2026

Adial Pharmaceuticals (ADIL) Slides 9.3% as Biotech Volatility ReturnsSector Leader Stocks - dars.gov.et

Aug 15, 2026
pulisher
Aug 15, 2026

Adial Pharmaceuticals (ADIL) Slides 9.3% as Biotech Volatility ReturnsWyckoff Spring - vinanet.vn

Aug 15, 2026
pulisher
Aug 14, 2026

Adial Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 14, 2026
pulisher
Aug 14, 2026

Adial Pharmaceuticals (NASDAQ: ADIL) lifts cash to $28.7M but flags going‑concern risk - Stock Titan

Aug 14, 2026
pulisher
Aug 13, 2026

Form 8K Adial Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Canada

Aug 13, 2026
pulisher
Aug 13, 2026

Form 8K Adial Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Nigeria

Aug 13, 2026
pulisher
Aug 13, 2026

Adial Pharmaceuticals plans leadership changes tied to annual meeting vote - Investing.com

Aug 13, 2026
pulisher
Aug 13, 2026

Adial Pharmaceuticals plans leadership changes tied to annual meeting vote - Investing.com

Aug 13, 2026
pulisher
Aug 13, 2026

Adial Pharmaceuticals Plans Major Leadership and Board Transition - TipRanks

Aug 13, 2026

Adial Pharmaceuticals Inc (ADIL) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Adial Pharmaceuticals Inc 주식 (ADIL) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Coastlands Capital LP
10% Owner
Jul 16 '26
Buy
2.75
1,233
3,391
388,308
Coastlands Capital LP
10% Owner
Jul 10 '26
Buy
2.70
1,700
4,590
385,075
Coastlands Capital LP
10% Owner
Jul 09 '26
Buy
2.79
10,053
28,048
383,375
Coastlands Capital LP
10% Owner
Jun 29 '26
Buy
2.60
25,000
65,000
373,322
$6.58
price down icon 4.22%
$9.94
price down icon 3.21%
$5.53
price down icon 3.66%
$11.27
price down icon 6.16%
$18.60
price down icon 1.74%
WVE WVE
$3.13
price down icon 1.88%
자본화:     |  볼륨(24시간):